Reports and Commentaries

Innogen Policy Briefs

Appropriate Governance of the Life Sciences Series (2008-2012)

Multinational Company Innovation Strategies
Joyce Tait

The Case for Smart Regulation
Joyce Tait, Joanna Chataway and David Wield

Regulating GM Crops: lessons for next generation technologies
Joyce Tait, Ann Bruce, Joanna Chataway, David Wield

Pharmaceutical Futures: Health biotechnology to 2030
Joyce Tait, Joanna Chataway and David Wield

Health Innovation for the world’s poor: Who are the players and what is the game?
Joanna Chataway, Rebecca Hanlin, Joyce Tait and David Wield

Where are Product Development Partnerships (PDPs) headed and how can THeSyS help them get there?
Joanna Chataway, Rebecca Hanlin, Julius Mugwagwa and Lois Muraguri

Interrogating the feasibility of cross-national cooperation in technology governance: the case of biosafety in southern Africa
Julius Mugwagwa

Smarter Regulation of Drug Development: FDA Orphan Products and Fast Track Programmes
Christopher-Paul Milne and Joyce Tait

Pros and Cons of the Precautionary Principle (PP): European Experience with the regulation of GM Crops
Joyce Tait and Joanna Chataway

Cross-national convergence of biosafety systems in Sub-Saharan Africa
Julius Mugwagwa

Governing Synthetic Biology
Joyce Tait

Innogen Working Papers

FINANCING AFRICAN LOCAL PHARMACEUTICAL PRODUCTION

Geoffrey Banda

THE EFFECT OF THE DYNAMICS OF KNOWLEDGE BASE COMPLEXITY ON SCHUMPETERIAN PATTERNS OF INNOVATION: THE UPSTREAM PETROLEUM INDUSTRY
Ali Maleki, Alessandro Rosiello and David Wield

PHARMACEUTICAL EVOLUTION: CLINICAL SELECTION VERSUS INTELLIGENT DESIGN
Jack W. Scannell

FOUR REASONS DRUGS ARE EXPENSIVE, OF WHICH TWO ARE FALSE
AN OPINION

Jack W. Scannell

IT’S NOT STI: IT’S ITS
THE ROLE OF SCIENCE, TECHNOLOGY AND INNOVATION (STI) IN AFRICA’S
DEVELOPMENT STRATEGY

Norman Clark and Andy Frost

THE IMAGINED HEALTH COMMUNITY: NARRATIVES OF SCOTTISH HEALTH AND
INDEPENDENCE

MicheIe Mastroeni, Elisabeth Barlow, James Mittra and David Wield